- Home
- JAZZ vs THG Comparison
JAZZ vs THG Comparison
Compare JAZZ & THG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- THG
- Stock Information
- Founded
- JAZZ 2003
- THG 1852
- Country
- JAZZ Ireland
- THG United States
- Employees
- JAZZ N/A
- THG N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- THG Property-Casualty Insurers
- Sector
- JAZZ Health Care
- THG Finance
- Exchange
- JAZZ Nasdaq
- THG Nasdaq
- Market Cap
- JAZZ 6.5B
- THG 5.6B
- IPO Year
- JAZZ 2007
- THG 1995
- Fundamental
- Price
- JAZZ $122.49
- THG $152.11
- Analyst Decision
- JAZZ Buy
- THG Buy
- Analyst Count
- JAZZ 14
- THG 7
- Target Price
- JAZZ $173.93
- THG $173.29
- AVG Volume (30 Days)
- JAZZ 539.6K
- THG 181.9K
- Earning Date
- JAZZ 11-06-2024
- THG 01-29-2025
- Dividend Yield
- JAZZ N/A
- THG 2.27%
- EPS Growth
- JAZZ 458.10
- THG N/A
- EPS
- JAZZ 7.04
- THG 10.00
- Revenue
- JAZZ $3,992,712,000.00
- THG $6,181,900,000.00
- Revenue This Year
- JAZZ $7.51
- THG N/A
- Revenue Next Year
- JAZZ $6.82
- THG $5.13
- P/E Ratio
- JAZZ $17.38
- THG $15.21
- Revenue Growth
- JAZZ 5.23
- THG 4.01
- 52 Week Low
- JAZZ $99.06
- THG $119.36
- 52 Week High
- JAZZ $134.17
- THG $166.13
- Technical
- Relative Strength Index (RSI)
- JAZZ 53.16
- THG 35.83
- Support Level
- JAZZ $121.22
- THG $153.74
- Resistance Level
- JAZZ $126.23
- THG $155.72
- Average True Range (ATR)
- JAZZ 2.83
- THG 2.59
- MACD
- JAZZ -0.23
- THG -1.53
- Stochastic Oscillator
- JAZZ 50.43
- THG 3.39
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About THG Hanover Insurance Group Inc
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through three operating segments: Commercial Lines, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.